(2025) NHS [accessed 30 January 2026] The effect of chewing sugar-free gum on gastro-esophageal reflux
Trials have shown that a once-weekly injection of 2.4 mg of semaglutide in people who are overweight or obese can lead to an average loss of 15% body weight which persisted for the 104 weeks of medication use
By combining GLP-1, GIP, and glucagon receptor activity, these therapies may enhance appetite suppression, improve insulin sensitivity, and increase energy expenditure
The reconstitution process is identical, but the math and practical considerations change in important ways
Patients should aim to stay active, maintain a healthy weight, and avoid prolonged periods of immobility
Get care developed by in-house experts with decades of clinical excellence